Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic MalformationsCardiovascular Abnormalities, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Lymphatic Abnormalities, Neoplasm, Lymphatic Tissue, Neoplasms by Histologic Type, cardiovascular disorder, lymphangioma, lymphatic system disorder, microcystic lymphatic malformation, neoplasm, vascular malformationActive, not recruitingPhase 32026-03-27NCT06239480

2 results · Page 1 of 1

Swipe the table sideways for more columns.

15 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Children's Healthcare of AtlantaAtlantaUnited States15
Children's Hospital of Orange CountyIrvineUnited States2
Children's Hospital of PhiladelphiaPhiladelphiaUnited States434
Cincinnati Children's HospitalCincinnatiUnited States66
Cleveland ClinicClevelandUnited States558
Mayo ClinicRochesterUnited States664
Minnesota Clinical Study CenterNew BrightonUnited States13
Penn State Hershey Medical CenterHersheyUnited States19
Stanford UniversityPalo AltoUnited States51
Texas Children's HospitalHoustonUnited States187
University of North CarolinaChapel HillUnited States5
University of Texas, Dell Children'sAustinUnited States1
University of Utah HealthSalt Lake CityUnited States2
Vanderbilt Children's HospitalNashvilleUnited States7
Vascular Birthmark InstituteNew YorkUnited States1